一種新型支架叫做Genous生物工程R支架，是以天然愈合途徑為基礎(chǔ)，對(duì)抗血栓形成并將血管狹窄降低至最小。該支架已經(jīng)獲得了CE標(biāo)志。

這種Genous支架的開(kāi)發(fā)商是香港的OrbusNeich公司，該公司已經(jīng)被挑選為Frost & Sullivan (Palo Alto, CA, USA)2005年技術(shù)創(chuàng)新獎(jiǎng)的獲得者。每年，這項(xiàng)大獎(jiǎng)授予那些開(kāi)展新研究并導(dǎo)致創(chuàng)新的公司，這些研究已經(jīng)或者即將對(duì)產(chǎn)業(yè)帶來(lái)顯著的貢獻(xiàn)。

Genous支架能夠以快速和可控制的方式促進(jìn)組織愈合，而不是抑制愈合，包括內(nèi)皮細(xì)胞覆蓋，強(qiáng)大的抗增殖藥物釋放支架。一項(xiàng)正在進(jìn)行的臨床研究叫做HEALING II(健康內(nèi)皮細(xì)胞加速排列抑制新血管內(nèi)皮生長(zhǎng))，其初步研究結(jié)果的分析顯示，接受該支架的患者疾病的臨床轉(zhuǎn)歸較好。一項(xiàng)HEALING III多因素臨床研究不久即將開(kāi)始，評(píng)估Genous的Statin治療與無(wú)覆蓋金屬支架的療效。

“Genous不是一種藥物釋放支架，沒(méi)有聚合體或者藥物。 ” 銷(xiāo)售與市場(chǎng)部副總裁David Camp指出。“這種支架使用抗體進(jìn)行覆蓋，能夠捕獲患者自身循環(huán)中內(nèi)皮細(xì)胞的祖細(xì)胞。這樣不僅能夠?qū)⒃侏M窄的可能降至最小，而且提供了對(duì)抗血栓的即時(shí)保護(hù)。”

OrbusNeich為全球60多個(gè)國(guó)家提供血管疾病的醫(yī)療設(shè)備。
 
Stent Promotes Tissue Healing
 
A new stent called the Genous bio-engineered R stent is based on a natural healing approach to protect against thrombus and to minimize stenosis. The stent has received the CE Mark.

The developer of the Genous stent, OrbusNeich (Hong Kong) has been selected as the recipient of a 2005 Technology Innovation Award from Frost & Sullivan (Palo Alto, CA, USA). Each year, this award is given to a company that has carried out new research resulting in innovations that have, or will, bring significant contributions to industry.

Genous stents promote tissue healing to occur in a rapid and controlled manner at the stent injury, rather than inhibiting healing, including endothelial coverage, with potent antiproliferative drug-eluting stents. An analysis of interim results of an ongoing clinical study called HEALING II (healthy endothelial accelerated lining inhibits neointimal growth) show that the patients who received the stent and were also on statins had better clinical outcomes. A HEALING III multifactorial clinical study will begin soon to assess the effect of statin therapy with Genous vs bare metal stents.

“Genous is not a drug-eluting stent, there is no polymer or drug,” said David Camp, vice president, sales and marketing. “The stent is coated with an antibody that captures a patient’s own circulating endothelial progenitor cells. This not only minimizes restenosis but also provides immediate protection against thrombus.”

OrbusNeich supplies medical devices for vascular diseases in more than 60 countries around the world.